1-7 of 7
glucagon-like peptide 1
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Metformin Improves Glycemic Control and Postprandial Metabolism and Enhances Postprandial Glucagon-Like Peptide 1 Secretion in Patients With Type 2 Diabetes and Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial

Vojtěch Melenovský, Eva Hošková, Kateřina Velebová, Jiří Veleba, Barry A. Borlaug, Jan Benes, Ondřej Kuda, Tomáš Čajka, Markéta Segeťová, Lenka Thieme, Jan Kopecký, Jr., Jan Kopecký, Sr., Terezie Pelikánová, Martin Haluzík, Martin Hill, Hana Kahleová
Journal: Clinical Diabetes
Clin Diabetes cd240003
https://doi.org/10.2337/cd24-0003
Published: 09 September 2024
View article titled, Metformin Improves Glycemic Control and Postprandial Metabolism and Enhances Postprandial Glucagon-Like Peptide 1 Secretion in Patients With Type 2 Diabetes and Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial
Open the PDF for Metformin Improves Glycemic Control and Postprandial Metabolism and Enhances Postprandial Glucagon-Like Peptide 1 Secretion in Patients With Type 2 Diabetes and Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial in another window
Journal Articles

Erratum: Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages. Clinical Diabetes 2023;41:467–473

Heather P. Whitley, Jennifer M. Trujillo, Joshua J. Neumiller
Journal: Clinical Diabetes
Clin Diabetes 2024;42(4):583
https://doi.org/10.2337/cd24-er04
Published: 13 August 2024
View article titled, Erratum: Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages. Clinical Diabetes 2023;41:467–473
Open the PDF for Erratum: Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages. Clinical Diabetes 2023;41:467–473 in another window
Journal Articles

Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 Diabetes

Roy W. Beck, Carol J. Levy, Yogish C. Kudva, Keta Pandit, Thomas Blevins, Dan Raghinaru, Jordan E. Pinsker
Journal: Clinical Diabetes
Clin Diabetes 2024;42(4):547–549
https://doi.org/10.2337/cd23-0107
Published: 17 April 2024
View article titled, Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 Diabetes
Open the PDF for Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 Diabetes in another window
Journal Articles

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages

Heather P. Whitley, Jennifer M. Trujillo, Joshua J. Neumiller
Journal: Clinical Diabetes
Clin Diabetes 2023;41(3):467–473
https://doi.org/10.2337/cd23-0023
Published: 07 April 2023
View article titled, Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
Open the PDF for Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages in another window
Journal Articles

Rationale for the Use of Combination Injectable Therapy in Patients With Type 2 Diabetes Who Have High A1C (≥9%) and/or Long Duration (>8 Years): Executive Summary

Vivian A. Fonseca, Minisha Sood, Rodolfo J. Galindo
Journal: Clinical Diabetes
Clin Diabetes 2021;39(2):141–145
https://doi.org/10.2337/cd20-0121
Published: 01 April 2021
View article titled, Rationale for the Use of Combination Injectable Therapy in Patients With Type 2 Diabetes Who Have High A1C (≥9%) and/or Long Duration (>8 Years): Executive Summary
Open the PDF for Rationale for the Use of Combination Injectable Therapy in Patients With Type 2 Diabetes Who Have High A1C (≥9%) and/or Long Duration (>8 Years): Executive Summary in another window
Journal Articles

Diabetes Has Gotten Pretty Darn Complicated

Neil Skolnik, Anupriya Grover
Journal: Clinical Diabetes
Clin Diabetes 2015;33(3):114–115
https://doi.org/10.2337/diaclin.33.3.114
Published: 01 July 2015
View article titled, Diabetes Has Gotten Pretty Darn Complicated
Open the PDF for Diabetes Has Gotten Pretty Darn Complicated in another window
Journal Articles

Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide

Kathleen Dungan, MD, John B. Buse, MD, PhD
Journal: Clinical Diabetes
Clin Diabetes 2005;23(2):56–62
https://doi.org/10.2337/diaclin.23.2.56
Published: 01 April 2005
View article titled, Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide
Open the PDF for Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide in another window